Dopamine D2-type agonists protect mesencephalic neurons from glutamate neurotoxicity: Mechanisms of neuroprotective treatment against oxidative stress

Annals of Neurology

Volumn 44, Issue 1, 1998, Pages 110-119

  Sawada, Hideyuki ^a   Ibi, Masakazu ^a   Kihara, Takeshi ^a   Urushitani, Makoto ^a   Akaike, Akinori ^a   Kimura, Jun ^a   Shimohama, Shun ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BROMOCRIPTINE; CALCIUM IONOPHORE; DOPAMINE 2 RECEPTOR; FREE RADICAL; GLUTAMIC ACID; HYDROGEN PEROXIDE; QUINPIROLE; REACTIVE OXYGEN METABOLITE; SUPEROXIDE;

ANIMAL CELL; ARTICLE; CELL CULTURE; DEGENERATIVE DISEASE; DRUG ACTIVITY; MESENCEPHALON; NERVE CELL; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; RECEPTOR INTRINSIC ACTIVITY;

ANIMALS; BROMOCRIPTINE; CALCIMYCIN; CELLS, CULTURED; DOPAMINE AGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; FREE RADICAL SCAVENGERS; GLUTAMIC ACID; HYDROGEN PEROXIDE; HYPOXANTHINE; IONOPHORES; MESENCEPHALON; MICROSCOPY, CONFOCAL; NEURONS; NEUROPROTECTIVE AGENTS; OXIDANTS; OXIDATIVE STRESS; QUINPIROLE; RATS; XANTHINE OXIDASE;

EID: 0031927090     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.410440117     Document Type: Article

References (54)

1. Naoi M, Maruyama W, Niwa T, Nagatsu T. Novel toxins and Parkinson's disease: N-methylation and oxidation as metabolic bioactivation of neurotoxin. J Neural Transm Suppl 1994;41: 197-205
2. Mattammal MB, Haring JH, Chung HD, et al. An endogenous dopaminergic neurotoxin: implication for Parkinson's disease. Neurodegeneration 1995;4:271-281
3. Armstrong M, Daly AK, Cholerton S, et al. Mutant debrisoquine hydroxylation genes in Parkinson's disease. Lancet 1992; 339:1017-1018
4. Smith CA, Gough AC, Leigh PN, et al. Debrisoquine hydroxylase gene polymorphism and susceptibility to Patkinson's disease. Lancet 1992;339:1375-1377
5. Ikebe S, Tanaka M, Ozawa T. Point mutations of mitochondrial genome in Parkinson's disease. Mol Brain Res 1995;28: 281-295
6. Matsumine H, Saito M, Shimoda Matsubayashi S, et al. Localization of a gene for an autosomal recessive form of juvenile parkinsonism to chromosome 6q25.2-27. Am J Hum Genet 1997;60:588-596
7. Polymeropoulos MH, Lavedan C, Leroy E, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 1997;276:2045-2047
8. Jenner P. Oxidative stress as a cause of Parkinson's disease. Acta Neurol Scand Suppl 1991;136:6-15
9. Adams JD Jr, Odunze IN. Oxygen free radicals and Parkinson's disease. Free Radic Biol Med 1991;10:161-169
10. Floyd RA, Carney JM. Free radical damage to protein and DNA: mechanisms involved and relevant observations on brain undergoing oxidative stress. Ann Neurol 1992;32(Suppl):S22-S27
11. Olanow CW. An introduction to the free radical hypothesis in Parkinson's disease. Ann Neurol 1992;32(Suppl):S2-S9
12. Fahn S, Cohen G. The oxidant stress hypothesis in Parkinson's disease: evidence supporting it. Ann Neurol 1992;32:804-812
13. Halliwell B. Reactive oxygen species and the central nervous system. J Neurochem 1992;59:1609-1623
14. Hamberger A, Chiang GH, Sandoval E, Cotman CW. Glutamate as a CNS transmitter. II. Regulation of synthesis in the releasable pool. Brain Res 1979;168:531-541
15. Berdichevsky E, Riveros N, Sanchez Armass S, Orrego F. Kainate, N-methylaspartate and other excitatory amino acids increase calcium influx into rat brain cortex cells in vitro. Neurosci Lett 1983;36:75-80
16. Choi DW. Glutamate neurotoxicity in cortical cell culture is calcium dependent. Neurosci Lett 1985;58:293-297
17. Dawson VL, Dawson TM, Bartley DA, et al. Mechanisms of nitric oxide-mediated neurotoxicity in primary brain cultures. J Neurosci 1993;13:2651-2661
18. Bondy SC, Lee DK. Oxidative stress induced by glutamate receptor agonists. Brain Res 1993;610:229-233
19. Culcasi M, Lafon Cazal M, Pietri S, Bockaert J. Glutamate receptors induce a burst of Superoxide via activation of nitric oxide synthase in arginine-depleted neurons. J Biol Chem 1994; 269:12589-12593
20. Akaike A, Tamura Y, Yokota T, et al. Nicotine-induced protection of cultured cortical neurons against N-methyl-D-asparrate receptor-mediated glutamate cytotoxicity. Brain Res 1994;644:181-187
21. Amano T, Ujihara H, Matsubayashi H, et al. Dopamine-induced protection of striatal neurons against kainate receptor-mediated glutamate cytotoxicity in vitro. Brain Res 1994;655: 61-69
22. Kashii S, Takahashi M, Mandai M, et al. Protective action of dopamine against glutamate neurotoxicity in the retina. Invest Ophthalmol Vis Sci 1994;35:685-695
23. Kihara T, Shimohama S, Sawada H, et al. Nicotinic receptor stimulation protects neurons against beta-amyloid toxicity. Ann Neurol 1997;42:159-163
24. Reinoso BS, Undie AS, Levitt P. Dopamine receptors mediate differential morphological effects on cerebral cortical neurons in vitro. J Neurosci Res 1996;43:439-453
25. Yanagisawa N, Kanazawa I, Goto I, et al. Seven-year follow-up study of bromocriptine therapy for Parkinson's disease. Eur Neurol 1994;3:29-35
26. Lange KW, Rausch WD, Gsell W, et al. Neuroprotection by dopamine agonists. J Neural Transm Suppl 1994;43:183-201
27. Lees AJ, Parkinson's disease research group of United Kingdom. Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. BMJ 1995;311:1602-1607
28. LeWitt PA. Neuroprotection by anti-oxidant strategies in Parkinson's disease. Eur Neurol 1993;33(Suppl):S24-S30
29. Montastruc JL, Rascol O, Senard JM, Rascol A. A randomised controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson's disease: a five year follow up. J Neurol Neurosurg Psychiatry 1994;57:1034-1038
30. Tashiro K, Goto I, Kanazawa I, et al. Eight-year follow-up study of bromocriptine monotherapy for Parkinson's disease. Eur Neurol 1996;1:32-37
31. +) enhances glutamate-induced cytotoxicity against dopaminergic neurons in cultured rat mesencephalon. J Neurosci Res 1996;43:55-62
32. Sawada H, Kawamura T, Shimohama S, et al. Different mechanisms of glutamate-induced neuronal death between dopaminergic and non-dopaminergic neurons in rat mesencephalic culture. J Neurosci Res 1996;43:503-510
33. LeBel CP, Ischiropoulos H, Bondy SC. Evaluation of the probe 2′,7′-dichlorofluorescein as an indicator of reactive oxygen species formation and oxidative stress. Chem Res Toxicol 1992;5: 227-231
34. Kikuchi S, Kim SU. Glutamate neurotoxicity in mesencephalic dopaminergic neurons in culture. J Neurosci Res 1993;36:558-569
35. Ogawa N. Possible neuroprotective therapy for Parkinson's disease. Acta Med Okayama 1995;49:179-185
36. Yoshikawa T, Minamiyama Y, Naito Y, Kondo M. Antioxidant properties of bromocriptine, a dopamine agonist. J Neurochem 1994;62:1034-1038
37. Kondo T, Ito T, Sugita Y. Bromocriptine scavenges methamphetamine-induced hydroxyl radicals and attenuates dopamine depletion in mouse striatum. Ann NY Acad Sci 1994;738: 222-229
38. Yamashita H, Kawakami H, Zhang YX, et al. Neuroprotective mechanism of bromocriptine. Lancet 1995;346:1305 (Letter)
39. Filloux F, Dawson TM, Wamsley JK. Localization of nigrostriatal dopamine receptor subtypes and adenylate cyclase. Brain Res Bull 1988;20:447-459
40. Meador Woodruff JH, Mansour A, Bunzow JR, et al. Distribution of D2 dopamine receptor mRNA in rat brain. Proc Natl Acad Sci USA 1989;86:7625-7628
41. Sesack SR, Aoki C, Pickel V. Ultrastructural localization of D2 receptor-like immunoreactivity in midbrain dopamine neurons and their striatal targets. J Neurosci 1994;14:88-106
42. Bunzow JR, Van Tol HH, Grandy DK, et al. Cloning and expression of a rat D2 dopamine receptor cDNA. Nature 1988; 336:783-787
43. Sokoloff P, Giros B, Martres MP, et al. Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature 1990;347:146-151
44. Van Tol HH, Bunzow JR, Guan HC, et al. Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine. Nature 1991;350:610-614
45. Sunahara RK, Guan HC, O'Dowd BF, et al. Cloning of the gene for a human dopamine D5 receptor with higher affinity for dopamine than D1. Nature 1991;350:614-619
46. Marchetti C, Carbone E, Lux HD. Effects of dopamine and noradrenaline on Ca channels of cultured sensory and sympathetic neurons of chick. Pflugers Arch 1986;406:104-111
47. Vallar L, Meldolesi J. Mechanisms of signal transduction at the dopamine D2 receptor. Trends Pharmacol Sci 1989;10:74-77
48. Bigornia L, Allen CN, Jan CR, et al. D2 dopamine receptors modulate calcium channel currents and catecholamine secretion in bovine adrenal chromaffin cells. J Pharmacol Exp Ther 1990; 252:586-592
49. Lee AK. Dopamine (D2) receptor regulation of intracellular calcium and membrane capacitance changes in rat melanotrophs. J Physiol (Lond) 1996;495:627-640
50. Sauer H, Rosenblad C, Bjorklund A. Glial cell line-derived neurotrophic factor but not transforming growth facror beta 3 prevents delayed degeneration of nigral dopaminergic neurons following striatal 6-hydroxydopamine lesion. Proc Natl Acad Sci USA 1995;92:8935-8939
51. Kearns CM, Gash DM. GDNF protects nigral dopamine neurons against 6-hydroxydopamine in vivo. Brain Res 1995;672: 104-111
52. Kearns CM, Cass WA, Smoot K, et al. GDNF protection against 6-OHDA: time dependence and requirement for protein synthesis. J Neurosci 1997;17:7111-7118
53. Choi-Lundberg DL, Lin Q, Chang Y-N, et al. Dopaminergic neurons protected from degeneration by GDNF therapy. Science 1997;275:838-841
54. Liu XH, Kato H, Chen T, et al. Bromocriptine protects against delayed neuronal death of hippocampal neurons following cerebral ischemia in the gerbil. J Neurol Sci 1995;129:9-14